Zhehao Xu

Sir Run Run Shaw Hospital
Hangzhou, 310016, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

ALYREF-mediated m5C modification of CCNA1 drives escape from cell-cycle arrest and contributes to pazopanib resistance in Renal Cell Carcinoma.

ALYREF-mediated m5C modification of CCNA1 drives escape from cell-cycle arrest and contributes to pazopanib resistance in Renal Cell Carcinoma.

Journal: International journal of biological sciences

Published: January 13, 2026

Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer.

Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 30, 2025

PUS1 Drives Renal Cancer Progression by Preventing Formation of Endogenous Double-stranded RNAs.

PUS1 Drives Renal Cancer Progression by Preventing Formation of Endogenous Double-stranded RNAs.

Journal: International journal of biological sciences

Published: December 18, 2025

Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine.

Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine.

Journal: Cancer research

Published: November 09, 2024

piR-RCC Suppresses Renal Cell Carcinoma Progression by Facilitating YBX-1 Cytoplasm Localization.

piR-RCC Suppresses Renal Cell Carcinoma Progression by Facilitating YBX-1 Cytoplasm Localization.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: November 05, 2024

The Quiet Giant: Identification, Effectors, Molecular Mechanism, Physiological and Pathological Function in mRNA 5-methylcytosine Modification.

The Quiet Giant: Identification, Effectors, Molecular Mechanism, Physiological and Pathological Function in mRNA 5-methylcytosine Modification.

Journal: International journal of biological sciences

Published: July 23, 2024

m6Am Methyltransferase PCIF1 Promotes LPP3 Mediated Phosphatidic Acid Metabolism and Renal Cell Carcinoma Progression.

m6Am Methyltransferase PCIF1 Promotes LPP3 Mediated Phosphatidic Acid Metabolism and Renal Cell Carcinoma Progression.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 16, 2024

The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma.

The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma.

Journal: Aging

Published: September 14, 2023

Comprehensive analysis of subtypes and risk model based on complement system associated genes in ccRCC.

Comprehensive analysis of subtypes and risk model based on complement system associated genes in ccRCC.

Journal: Cellular signalling

Published: June 29, 2023

Identification and validation of SERPINE1 as a prognostic and immunological biomarker in pan-cancer and in ccRCC.

Identification and validation of SERPINE1 as a prognostic and immunological biomarker in pan-cancer and in ccRCC.

Journal: Frontiers in pharmacology

Published: April 28, 2023

HIF1A-repressed PUS10 regulates NUDC/Cofilin1 dependent renal cell carcinoma migration by promoting the maturation of miR-194-5p.

HIF1A-repressed PUS10 regulates NUDC/Cofilin1 dependent renal cell carcinoma migration by promoting the maturation of miR-194-5p.

Journal: Cell & bioscience

Published: February 15, 2023

Showing 1-11 of 11

Last Updated: 09/26/2026